Skip to main content

Capital Markets Update

When:

June 15, 2016 8:00 amJune 15, 2016 10:00 am (PDT)

Where:

Illumina Theatre at the Alexandria
10996 Torreyana Road
San Diego, CA 92121

Registration Closed

Capital Markets Update

Could it be? After decades of frequent stomach-churning rides, has the biotechnology industry outgrown its label as “Emerging Sector?” Today, there are 2500 U.S. biotech companies, including more than 400 traded on major public market exchanges. The number of biotech companies with more than $1 billion in market capitalization has gone up 3x during the last five years. We have a robustly capitalized biotech sector today.

Access to capital markets is a key driver of success for our life science industry members. Join us on Wednesday, June 15th to learn more about the state of the capital markets in our region, gain valuable insight, and receive actionable intelligence. A panel of knowledgeable experts will answer important questions such as:
  • What are the notable deals that are getting done in today’s environment?
  • What is the optimal time to close a financing?
  • What are the most important milestones driving valuations for therapeutics, medical devices, and diagnostics?
  • What are the pros and cons of different forms equity financing today?
  • How should companies consider non-dilutive financing options?

Moderator:
Mike White, Managing Director, Life Sciences, Silicon Valley Bank

Speakers:
Peter Calveley, Director, Leerink Partners
Cheston Larson, Partner, Latham and Watkins
Zak Zimmerman, CEO, Forge Therapeutics


*Please note: This event is only open to industry companies and closed to all service providers of Biocom. A service provider is a company that does not directly work with a substance that needs approval by the FDA and/or does business-to-business sales. They provide a service to the biotechnology and pharmaceutical industry and includes, but is not limited to, law firms, banks, laboratory equipment suppliers, consulting firms, or IT services.

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2016-06-10

0

Refund before

Refund Before

Non-Member (Industry Company Only)

Today’s Price: 40

Important Dates

Amount

Registration before 2016-05-29T06:59:00.000+0000

Registration before

Registration before

Registration cost

40

Refund before 2016-06-10

40

Refund before

Refund Before

Non-Member (Industry Company Only)

Today’s Price: 40

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

40

Refund before 2016-06-10

40

Refund before

Refund Before

  • Speaker Bios
    Cheston Larson, Partner, Latham & Watkins

    Cheston Larson is a partner at Latham & Watkins LLP and serves as co-chair of the firm’s Life Sciences Industry Group.  Mr. Larson advises companies through the formation of new businesses and their capital raising transactions, spanning the spectrum from angel and venture financings to IPOs, follow-on offerings, PIPEs and debt financing.  Mr. Larson has extensive experience in SEC disclosure and reporting requirements, corporate governance matters and Nasdaq and NYSE compliance.  Mr. Larson also routinely counsels companies through M&A and other strategic transactions.  In addition to life sciences company representations, Mr. Larson frequently represents venture capital and investment banking firms in private and public financing transactions. Mr. Larson earned his JD from Harvard Law School in 1997, where he was an editor of the Harvard Law Review and worked for the US Securities and Exchange Commission's Enforcement Division as part of Harvard's Clinical Practice Program. He earned his BS in Finance from Georgetown University in 1994.

    Zak Zimmerman, CEO, Forge Therapeutics

    Zachary Zimmerman, Ph.D. is a founder and CEO of Forge Therapeutics having over 15 years of biotechnology start-up experience holding various business and scientific positions at Arcturus Therapeutics (Chief Business Officer), Regulus Therapeutics (Senior Director Corporate Development), and Alnylam Pharmaceuticals (Director Business Development).  Dr. Zimmerman has successfully driven company growth through strategic alliances, financings and non-dilutive grant awards; including the Regulus Therapeutics initial public offering raising $80.9M in gross proceeds and multiple therapeutic alliances with Astra Zeneca, Biogen, Cubist, GSK, Johnson & Johnson, Kyowa Hakko, and Takeda totaling $3.2B with over $200M in upfront cash payments.  Dr. Zimmerman has also led the strategic planning and execution of over $70M in non-dilutive grant funding from the Federal Government (NIH, DOD, DARPA, DTRA, and BARDA) and medical research foundations including the Cystic Fibrosis Foundation, Michael J. Fox Foundation, and Accelerate Brain Cancer Cures.  Dr. Zimmerman is a trained cellular biologist with expertise in drug discovery and development.  He was a post-doctoral fellow at Stanford University School of Medicine and earned his Ph.D. in Molecular, Cellular, and Developmental Biology at University of California, Santa Cruz.  

Registration Closed